{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-009743","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.681188+00:00","generated_at":"2026-05-17T12:16:17.234715+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies","bullets":["€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.","Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.","Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-009743","json":"https://secwatch.observer/filing/0001654954-25-009743.json","markdown":"https://secwatch.observer/filing/0001654954-25-009743.md","text":"https://secwatch.observer/filing/0001654954-25-009743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/0001654954-25-009743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:16:17.234715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}